comparative-oncology

A network run by the US National Cancer Institute in which veterinary schools test new cancer drugs in pet dogs with naturally occurring cancer, with their owners' consent, to help plan the first trials in people.

FidoCure sequences the tumours of dogs with cancer and matches them to targeted drugs, bringing precision medicine to veterinary oncology and building a dataset that also informs human cancer research.

Gamgee sequences a dog's tumour and designs a personalised mRNA vaccine that teaches its immune system what to attack, and is running trials in Australia with the aim of improving the approach with every case.

LEAH Labs makes CAR-T cell therapy for dogs with lymphoma, using virus-free gene editing to bring the cost of a dose down to hundreds of dollars.

Rabacfosadine (Tanovea) is an intravenous drip for dogs with lymphoma, conditionally approved by the US Food and Drug Administration in 2016 and fully approved in 2021. It is a medicine for dogs and is not used in people.

Tigilanol tiglate (Stelfonta) is an injection into the tumour, approved by the US Food and Drug Administration in 2020 to treat mast cell tumours in dogs. In people it is still experimental and is being tested in sarcoma and head and neck cancer.

Toceranib (Palladia) is a tablet for dogs, not people, approved by the US Food and Drug Administration in 2009 to treat mast cell tumours of the skin that have come back. It blocks the same family of growth signals as the human cancer drug sunitinib.

Verdinexor (Laverdia) is a tablet for dogs with lymphoma, the first oral lymphoma treatment for dogs to gain full approval from the US Food and Drug Administration. It works the same way as the human myeloma drug selinexor.